Evolva Holding SA (EVE.SW)
CHF 0.84
(-6.44%)
CHF 0.84
(-6.44%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -2.58 Million CHF | 146.74% |
| 2022 | -8.89 Million CHF | 42.9% |
| 2021 | -15.57 Million CHF | -57.08% |
| 2020 | -9.91 Million CHF | -302.92% |
| 2019 | -2.46 Million CHF | -216.23% |
| 2018 | 2.11 Million CHF | -1.47% |
| 2017 | 2.14 Million CHF | 108.14% |
| 2016 | -26.4 Million CHF | -13.49% |
| 2015 | -23.26 Million CHF | -73.54% |
| 2014 | -13.4 Million CHF | -31.81% |
| 2013 | -10.16 Million CHF | 18.71% |
| 2012 | -12.5 Million CHF | 23.78% |
| 2011 | -16.41 Million CHF | -188.11% |
| 2010 | 18.62 Million CHF | -1.58% |
| 2009 | 18.92 Million CHF | 4359.59% |
| 2008 | 424.4 Thousand CHF | 157.98% |
| 2007 | 164.51 Thousand CHF | -39.86% |
| 2006 | 273.56 Thousand CHF | 0.0% |
| 2005 | - CHF | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | - CHF | 0.0% |
| 2023 Q2 | -3.24 Million CHF | 0.0% |
| 2023 Q4 | -5.72 Million CHF | 0.0% |
| 2023 FY | 4.15 Million CHF | 146.74% |
| 2022 Q2 | -5.87 Million CHF | 0.0% |
| 2022 Q4 | -3.01 Million CHF | 0.0% |
| 2022 FY | -8.89 Million CHF | 42.9% |
| 2021 FY | -15.57 Million CHF | -57.08% |
| 2021 Q4 | -6.15 Million CHF | 0.0% |
| 2021 Q2 | -9.91 Million CHF | 0.0% |
| 2020 FY | -9.91 Million CHF | -302.92% |
| 2020 Q2 | -4.26 Million CHF | 0.0% |
| 2020 Q4 | -5.64 Million CHF | 0.0% |
| 2019 FY | -2.46 Million CHF | -216.23% |
| 2019 Q2 | -767.8 Thousand CHF | 0.0% |
| 2019 Q4 | -1.69 Million CHF | 0.0% |
| 2018 FY | 2.11 Million CHF | -1.47% |
| 2018 Q2 | 961.7 Thousand CHF | 0.0% |
| 2018 Q4 | 1.15 Million CHF | 0.0% |
| 2017 Q2 | -11.74 Million CHF | 0.0% |
| 2017 FY | 2.14 Million CHF | 108.14% |
| 2017 Q4 | -7.43 Million CHF | 0.0% |
| 2016 FY | -26.4 Million CHF | -13.49% |
| 2016 Q2 | -13.41 Million CHF | 0.0% |
| 2016 Q4 | -12.98 Million CHF | 0.0% |
| 2015 FY | -23.26 Million CHF | -73.54% |
| 2015 Q4 | -12.56 Million CHF | 0.0% |
| 2015 Q2 | -10.69 Million CHF | 0.0% |
| 2014 Q4 | -6.84 Million CHF | 0.0% |
| 2014 FY | -13.4 Million CHF | -31.81% |
| 2014 Q2 | -6.55 Million CHF | 0.0% |
| 2013 Q4 | -4.58 Million CHF | 0.0% |
| 2013 FY | -10.16 Million CHF | 18.71% |
| 2013 Q2 | -5.58 Million CHF | 0.0% |
| 2012 FY | -12.5 Million CHF | 23.78% |
| 2012 Q4 | -2.54 Million CHF | 18.71% |
| 2012 Q1 | -3.12 Million CHF | 0.0% |
| 2012 Q2 | -3.12 Million CHF | -0.0% |
| 2012 Q3 | -3.12 Million CHF | 0.0% |
| 2011 Q1 | -4.1 Million CHF | 0.0% |
| 2011 Q2 | -4.1 Million CHF | 0.0% |
| 2011 Q3 | -4.1 Million CHF | 0.0% |
| 2011 Q4 | -3.12 Million CHF | 23.78% |
| 2011 FY | -16.41 Million CHF | -188.11% |
| 2010 FY | 18.62 Million CHF | -1.58% |
| 2010 Q4 | -4.1 Million CHF | -188.11% |
| 2010 Q3 | 4.65 Million CHF | 0.0% |
| 2010 Q2 | 4.65 Million CHF | 0.0% |
| 2010 Q1 | 4.65 Million CHF | 0.0% |
| 2009 Q2 | 4.73 Million CHF | 0.0% |
| 2009 Q4 | 4.65 Million CHF | -1.58% |
| 2009 Q3 | 4.73 Million CHF | 0.0% |
| 2009 FY | 18.92 Million CHF | 4359.59% |
| 2009 Q1 | 4.73 Million CHF | 0.0% |
| 2008 Q1 | 106.1 Thousand CHF | 0.0% |
| 2008 Q4 | 4.73 Million CHF | 4359.59% |
| 2008 Q3 | 106.1 Thousand CHF | 0.0% |
| 2008 FY | 424.4 Thousand CHF | 157.98% |
| 2008 Q2 | 106.1 Thousand CHF | 0.0% |
| 2007 Q3 | 41.12 Thousand CHF | 0.0% |
| 2007 Q1 | 41.12 Thousand CHF | 0.0% |
| 2007 Q4 | 106.1 Thousand CHF | 157.98% |
| 2007 FY | 164.51 Thousand CHF | -39.86% |
| 2007 Q2 | 41.12 Thousand CHF | 0.0% |
| 2006 Q3 | 68.39 Thousand CHF | 0.0% |
| 2006 Q2 | 68.39 Thousand CHF | 0.0% |
| 2006 Q1 | 68.39 Thousand CHF | 0.0% |
| 2006 FY | 273.56 Thousand CHF | 0.0% |
| 2006 Q4 | 41.12 Thousand CHF | -39.86% |
| 2005 FY | - CHF | 0.0% |
| 2005 Q4 | 68.39 Thousand CHF | 0.0% |
| 2005 Q3 | - CHF | 0.0% |
| 2005 Q2 | - CHF | 0.0% |
| 2005 Q1 | - CHF | 0.0% |
| 2004 Q4 | - CHF | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Addex Therapeutics Ltd | -5.31 Million CHF | 51.439% |
| BB Biotech AG | -199.56 Million CHF | 98.706% |
| Basilea Pharmaceutica AG | 130.84 Million CHF | 101.974% |
| Idorsia Ltd | 145.23 Million CHF | 101.778% |
| Kuros Biosciences AG | 22.87 Million CHF | 111.292% |
| Molecular Partners AG | -40.8 Million CHF | 93.671% |
| Relief Therapeutics Holding AG | -10.85 Million CHF | 76.217% |
| Santhera Pharmaceuticals Holding AG | 99.54 Million CHF | 102.594% |